SymBio Pharmaceuticals Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	1,308	2,452	5,589	10,008	8,257
Revenue	1,308	2,452	5,589	10,008	8,257
Revenue Growth (YoY)	-46.67%	-56.13%	-44.16%	21.21%	176.42%
Cost of Revenue	360.31	579	1,179	2,408	2,452
Gross Profit	947.34	1,873	4,410	7,600	5,804
Selling, General & Admin	2,091	2,371	2,584	3,082	3,048
Research & Development	3,297	3,379	2,638	2,554	1,736
Other Operating Expenses	-	-	-	-	4.34
Operating Expenses	5,388	5,750	5,222	5,636	4,788
Operating Income	-4,441	-3,877	-812	1,964	1,016
Interest Expense	-149.45	-	-	-	-
Interest & Investment Income	4.2	32	11	-	2.7
Currency Exchange Gain (Loss)	-64.96	172	117	136	-20.19
Other Non Operating Income (Expenses)	-21.37	-17	-45	-100	2.61
EBT Excluding Unusual Items	-4,672	-3,690	-729	2,000	1,001
Gain (Loss) on Sale of Assets	-	-	-7	-	-
Asset Writedown	-109.27	-131	-560	-	-
Other Unusual Items	8.54	14	101	106	0.2
Pretax Income	-4,749	-3,807	-1,195	2,106	1,001
Income Tax Expense	27.57	26	767	927	-1,031
Net Income	-4,776	-3,833	-1,962	1,179	2,032
Net Income to Common	-4,776	-3,833	-1,962	1,179	2,032
Net Income Growth	-	-	-	-41.98%	-
Shares Outstanding (Basic)	50	45	40	39	38
Shares Outstanding (Diluted)	50	45	40	40	39
Shares Change (YoY)	11.34%	13.02%	0.75%	1.97%	17.88%
EPS (Basic)	-95.12	-84.99	-49.17	30.19	53.04
EPS (Diluted)	-95.12	-84.99	-49.17	29.77	52.32
EPS Growth	-	-	-	-43.10%	-
Free Cash Flow	-4,576	-3,435	-398	1,612	114.59
Free Cash Flow Per Share	-91.13	-76.17	-9.97	40.70	2.95
Gross Margin	72.45%	76.39%	78.91%	75.94%	70.30%
Operating Margin	-339.59%	-158.12%	-14.53%	19.62%	12.31%
Profit Margin	-365.25%	-156.32%	-35.10%	11.78%	24.61%
Free Cash Flow Margin	-349.91%	-140.09%	-7.12%	16.11%	1.39%
EBITDA	-	-3,779	-714	2,063	1,110
EBITDA Margin	-	-154.12%	-12.78%	20.61%	13.44%
D&A For EBITDA	-	98	98	99	93.96
EBIT	-4,441	-3,877	-812	1,964	1,016
EBIT Margin	-	-158.12%	-14.53%	19.62%	12.31%
Effective Tax Rate	-	-	-	44.02%	-
Revenue as Reported	-	-	-	-	8,257
Advertising Expenses	-	692	937	1,481	1,643

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.